TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01197001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine plus Losartan
Description: Amlodipine/Losartan low dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine, Losartan
Description: Amlodipine, Losartan
Study: NCT03539809

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Amino Acids
Description: 6 different ratios of the Branched-chain Amino Acids (BCAA) will be tested for 8 hours each.
Study: NCT02288377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lanreotide
Description: Patients will receive lanreotide 120 mg every 28 days until disease progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02217072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School intervention
Description: A school-based intervention that builds on the promising Swedish programme SkolFam, but is adapted to a Danish school context. The two main components of the programme are a) comprehensive assessment of the child, involving testing of the child's cognitive and academic abilities and difficulties as well as an evaluation of the child's behaviour, school-related social relations and well-being, and b) a systematic and individually targeted intervention plan, made in collaboration between a psychologist, the teachers, and a special educational teacher at the school (e.g., the reading counsellor).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents as Tutors
Description: A home-based intervention, comprising a structured tutoring programme that allows foster parents to systematically support the foster child's school performance. Foster parents will attend an introductory tutor training seminar at which they will be introduced to relevant theory on learning and counselled on tutoring practice. The intervention itself is designed to provide approximately three hours per week of individual home-based tutoring for a period of 40 weeks.
Study: NCT02945722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decolonization
Description: Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days. Screening of persistent carriers will be done every 3 months
Study: NCT04156516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEART
Description: sexual health intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HealthyMinds
Description: Growth mindsets of personality and mental health
Study: NCT00320359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous topotecan/cisplatin
Description: Topotecan 1 mg/m2 should be administered intravenously over a period of 30 minutes on days 1-5. Then a 30 minute saline flush should be administered followed by the cisplatin on day 5.~Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 5 after topotecan.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous etoposide/cisplatin
Description: Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 1. Cisplatin should be given simultaneously to post-hydration to ensure a high volume fluid.~Etoposide 100 mg/m2 should be administered after cisplatin intravenously over a period not less than 30 minutes on days 1 -3.
Study: NCT01633580

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: corifollitropin alfa
Description: long acting FSH

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corifollitropin alfa
Description: long acting FSH
Study: NCT01329835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: 4 prenatal sessions based on principles of motivational interviewing and positive reinforcement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: brochure
Description: brochure given after randomization
Study: NCT00634270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: This phase II study will evaluate children and adults with neurofibromatosis type-1 (NF1) and plexiform neurofibromas treated with sirolimus. It is divided in two strata. The first stratum will evaluate time to progression (TTP) in children and adults with NF1 and progressive plexiform neurofibromas with the potential to cause significant morbidity treated with sirolimus. The second stratum will evaluate objective radiographic response to sirolimus in children and adults with NF1 and inoperable plexiform neurofibromas with the potential to cause significant morbidity that do not have documented progression of the PN at time of trial entry.
Study: NCT02254239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02945722

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No decolonization
Description: Screening of persistent carriers in this arm will be done every 3 months
Study: NCT05220033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational intervention
Description: Receive information focusing on coping skills for patients diagnosed with gynecologic cancer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies
Study: NCT02702349

Intervention type: OTHER
Group type: OTHER
Intervention: penicillin test
Description: children are tested for penicillin allergy and then challenged with penicillin P.O.
Study: NCT03750162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VDW Ultra
Description: supplementary disinfection technique

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMD picasso
Description: supplementary disinfection technique

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProtaperNext X3 gutta-percha
Description: supplementary disinfection technique
Study: NCT01928030

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant human hyaluronidase
Description: Given SC
Study: NCT03048448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fevipiprant
Description: Single 450mg dose
Study: NCT01635569

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group-based family cognitive-behavioural therapy
Description: Baseline and post-12 sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist
Description: Baseline and post-12 sessions
Study: NCT03096028

Intervention type: OTHER
Intervention: maternal vitamin B12 folate level during pregnancy
Description: Maternal Vitamin B12 and folate level at 18\&28 weeks of pregnancy is the primary exposure of interest
Study: NCT04334148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: oral self administered tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: oral self administered tablet
Study: NCT02167555

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Wild Blueberry Beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo Beverage
Study: NCT00538733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalomid
Description: Cycles 1-4~• Thalidomide (50mg daily for days 1-7, thereafter 100mg daily for days 8-28 of the first 28 day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 for each subsequent cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)~• Lenalidomide (25 mg daily days 1-21 of every 28 day cycle)~During BiRD phase • 25mg daily days 1-21 of every 28 day cycle)~During Maintenance Phase~• 25 mg daily for days 1-21 out of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin
Description: During T-BiRD Phase • Clarithromycin (500mg twice daily for each 28 day cycle)~During BiRD Phase:~• Clarithromycin (500mg twice daily for each 28 day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)~• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)~During BiRD Phase:~• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)~During Maintenance Phase~• Dexamethasone 20 mg weekly (days 1,8, 15, 22 out of a 28 day cycle)
Study: NCT00002708

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical procedure

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Study: NCT01971580

Intervention type: DRUG
Group type: OTHER
Intervention: Ambrisentan
Study: NCT01229670

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: exercise
Description: * 1.exercise(Aerobic interval training (AIT)): training with 90% of VO2 peak and 40% of VO2 peak cycle for total 30 minutes exercise time~* 2.exercise(moderate continuous training (MCT)):training with 60% of VO2peak for 30 min
Study: NCT04026516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAVA Device
Description: The CAVA device will be worn continuously for thirty days, during which time it will record eye and head movements
Study: NCT01712464

Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin vs. Placebo
Description: FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days

Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin vs. Placebo
Description: FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
Study: NCT05315869

Intervention type: PROCEDURE
Intervention: Appendectomy
Description: Surgical procedure for removal of the appendix

Intervention type: PROCEDURE
Intervention: Appendectomy
Description: Surgical procedure for removal of the appendix
Study: NCT00106535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 4 mg/kg or 8 mg/kg IV/month every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 4 mg/kg or 8 mg/kg IV/month every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV/month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: 10-25 mg/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 10-25 mg/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 10-25 mg/week
Study: NCT03721965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Phase 1: Itacitinib administered orally once daily at the protocol-defined dose according to age cohort, with dose reductions or modifications based on safety assessments. Phase 2: Itacitinib administered orally once daily at the recommended dose from Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Phase 1 and 2: Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose that is appropriate for the severity of disease as outlined per local treatment guidelines as background treatment.
Study: NCT04375696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyglucosamine L112
Description: Polyglucosamine; Ascorbic Acid; Tartaric Acid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dicalcium Phosphate; Microcrystalline Cellulose; Iron Oxide (yellow, brown, and black); Magnesium Stearate; Silicon Dioxide
Study: NCT00854295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NexGen LPS-Flex Mobile Bearing Knee
Description: Total Knee Replacement
Study: NCT02321150

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cautery
Description: * Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.~* Conjunctiva undermined at the recipient site.~* Relaxing incisions placed at the corners of the recipient site.~* Graft is slid into place~* Graft / host interface is gently dried with a Qtip~* Bipolar cautery is applied after grasping the graft and host conjunctiva gently between cautery forceps.~  * Power setting: 25.~ * Duration of cautery: 4 -5 seconds; the tissue should whiten and contract as desiccation and coagulation take place. Some charring may occur.~* Counter traction is applied to the conjunctiva as the cautery forceps are gently teased off~* Cautery is applied at the 4 apices of the graft then in between these points.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sutures
Description: * Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.~* Conjunctiva undermined at the recipient site.~* Graft is slid into place The graft is secured to host conjunctiva using 7 interrupted sutures
Study: NCT00937885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation of reminiscence
Study: NCT01653132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Incobotulinum Toxin A
Description: Twenty units (0.2 ml) of incobotulinum toxin A were injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile, preservative free 0.9% saline, 1 ml, was used as placebo, and injected into the parotid (0.2 ml each) and submandibular (0.3ml each) glands .
Study: NCT04690062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab-Dbll
Description: intravitreal injection of Brolucizumab (BEOVU)
Study: NCT02945046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to fremanezumab will be administered per schedule specified in the arm.
Study: NCT00567112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg MK-0941 DFC (fasted)
Description: single dose of 10 mg MK-0941 dry filled capsules (DFC) administered in a fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg MK-0941 OCT (after meal)
Description: single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered after consumption of a high-fat meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg MK-0941 OCT (before meal)
Description: single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered before consumption of a standard breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg MK-0941 OCT (fasted)
Description: single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered in a fasted state
Study: NCT01663077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: A fixed dose of Clozapine 300 mg/day (150 mg x 2)for 3 month
Study: NCT00425854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: high dose once daily
Study: NCT04474158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Creating Peace
Description: Creating Peace is a 12 session curriculum designed to support youth ages 14-19 in healing from experiences of trauma by restoring social connections, strengthening positive coping strategies that exclude all forms of violence, challenging gender norms that foster violence perpetration, and practicing positive bystander intervention skills to intervene safely with peers' disrespectful and harmful behaviors. Through 12 sessions (3 hours/session) over a 4 to 12 week period, Creating Peace offers gender transformative content combined with youth leadership development. Near program conclusion, youth will offer guidance to law enforcement on interacting with youth in a process of social restoration.
Study: NCT03223272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reserpine
Description: Open label reserpine 0.1 mg pill orally
Study: NCT01972334

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: as explained in study arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: salt water or saline will be given as placebo
Study: NCT04474158

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Job Readiness
Description: Job Readiness Training uses a group discussion format to learn specific skills to prepare for employment including developing goals, seeking jobs, preparing for interviews, and so forth.
Study: NCT00540423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-497115-GR 25mg
Description: SB-497115-GR 25mg tablet once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SB-497115-GR 12.5mg matching placebo
Description: SB-497115-GR 12.5mg matching placebo x1 or 2 tablet once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-497115-GR 50 mg
Description: SB-497115-GR 25mg tablet x2 once a day
Study: NCT02965898

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D 100ug
Description: Vitamin D 100 ug from Orion Pharma. Safest highest daily dose of vitamin D.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D 10ug
Description: Placebo dose. Minimal recommended dose.
Study: NCT03717805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: POAM
Description: The new 5 minutes preparatory information movie on oocyte aspiration (POAM) details what couples can expect to happen on the day of oocyte aspiration. More specifically, it describes the patient journey detailing which procedures will happen when and how, in which room, in the presence of their partner or not, and in the presence of which healthcare professionals.
Study: NCT00876967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: metallic single use blade
Description: metallic single use blade

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: plastic single use blade
Description: plastic single use blade

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: metallic reusable blade
Description: metallic reusable blade
Study: NCT03168659

Intervention type: DEVICE
Group type: OTHER
Intervention: HeartLight
Description: HeartLight Endoscopic Ablation System

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ablation
Description: Pulmonary vein isolation ablation
Study: NCT00982150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talampanel
Description: 50mg capsules tid
Study: NCT03677141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive oral prednisone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive oral prednisone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Participants will receive oral prednisone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive oral prednisone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive oral prednisone.
Study: NCT02642718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: In the operating room, the anesthesiologist administered ketorolac (30 mg) in 50 mL of 0.9 % saline intravenously to patients in the ketorolac group 30 minutes before surgical incision (a single dose).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the operating room, the anesthesiologist administered 50 mL of 0.9 % saline intravenously to patients in the control group 30 minutes before surgical incision
Study: NCT03677141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab via IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab via IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab via IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab via IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab via IV.
Study: NCT03747289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: performing exercises in a weight bearing posture
Description: 20 participants will perform exercises in a weight bearing posture
Study: NCT02307968

Intervention type: OTHER
Intervention: insulin injection site
Description: insulin injected site between inner thigh and out thigh
Study: NCT03747289

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: performing exercises in a non weight bearing posture
Description: 20 participants will perform exercises in a non weight bearing posture
Study: NCT00573950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilostazol
Description: 50 mg two times a day for 2 weeks and then 100mg two times a day for 6 weeks
Study: NCT03721471

Intervention type: OTHER
Intervention: Scoring of frailty
Description: 1. Patients will be scored by the Clinical frailty Scale~2. Patients' hand-grip-strength will be measured by a dynamometer.
Study: NCT05800262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic stability exercises
Description: A dynamic stability exercise program for daily home-exercise was applied during five physiotherapist led sessions distributed over seven weeks.